Skip to main content
OpenTrials
Completed

NCT Number: NCT02449213

A Biobehavioral Model of Diabetes Risk in Chinese Immigrants

This prospective, longitudinal study of Chinese American immigrants will examine whether psychosocial factors (e.g., acculturative stress, social isolation, discrimination) are associated with markers of type 2 diabetes risk over time, and whether such associations are mediated by inflammatory pathways.

Completed

Looking for future studies?

Notify Me

Key information

Age range

35 year–65 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Fox Chase Cancer Center

Philadelphia, Pennsylvania, 19111, United States

About this study

It is now well-documented that immigration to the US leads to increased risk for various chronic diseases, including type 2 diabetes. The increased diabetes risk observed among Chinese immigrants has been primarily attributed to changes in diet and weight gain following immigration, but these changes can only partially explain disparities in disease risk. Models of immigrant health suggest that the stress of adapting to life in a new country has a considerable impact on physical health. However, few studies have considered the psychosocial impact of immigration upon biomarkers of health and disease risk. Therefore, this longitudinal study of US Chinese immigrant men and women will examine: (1) whether psychosocial factors (e.g., acculturative stress, social isolation, discrimination) are associated with markers of type 2 diabetes risk over time; and (2) whether the association between psychosocial factors and diabetes risk markers is mediated by inflammatory pathways.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Chinese heritage;
  • migration from Asia in adulthood (aged 18 years or older); and
  • age 35-65 years

Exclusion criteria

  • Current or prior history of diabetes
  • Self-reported conditions of cancer, auto-immune disorders, HIV, or psychiatric illness
  • Use of medications that may impact study outcomes (e.g., steroidal or non-steroidal anti-inflammatory medications)
  • Inability to provide informed consent.

Treatment and study plan

Primary outcomes

  1. Insulin resistance

    Time frame: 24 months post-baseline

    Insulin resistance will be estimated according to the homeostasis model assessment (HOMA) as HOMA = (fasting insulin x fasting glucose) / 22.5

Secondary outcomes

  1. glycated hemoglobin (HbA1c)

    Time frame: 24-months post-baseline

    Level of blood sugar

Sponsors and collaborators

Lead sponsor

Fox Chase Cancer Center

Other

Registry information

Important dates

Study start
2016
Primary completion
2021
Study completion
2021
First posted
May 20, 2015
Registry last updated
Jun 4, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.